Aflibercept Patent
This MDL consolidates Biologics Price Competition and Innovation Act litigation brought by the manufacturer of the ophthalmic biologic aflibercept against multiple biosimilar developers, alleging infringement of a common set of thirteen patents covering the reference biologic product. Centralized in the Northern District of West Virginia in 2024, the docket originally named several biosimilar developers and has narrowed to 3 pending actions as some defendants settled and others litigated preliminary-injunction motions to distinct outcomes.
What makes this docket structurally distinctive is that different defendants within the same consolidated proceeding reached materially different results on the same core patent questions: appellate review affirmed preliminary injunctions against some biosimilar developers while a preliminary injunction was denied as to another, whose product has since launched in the U.S. market, and at least one other defendant settled on negotiated market-entry terms. That divergence, rather than a single docket-wide liability determination, is the central resolution dynamic here, and it reflects how patent-specific and product-specific factual differences among biosimilar formulations can produce genuinely different outcomes even under a shared patent-infringement theory.
For anyone tracking how BPCIA biosimilar patent litigation resolves, this docket is a clear illustration that consolidation for pretrial coordination does not mean a uniform outcome: claim-by-claim and defendant-by-defendant analysis remains essential even within a single MDL, since one biosimilar's product formulation or manufacturing process can support a materially different infringement or validity conclusion than another's. Criterica Intelligence's platform tracks this kind of defendant-level divergence within biosimilar patent MDLs rather than treating docket-wide status as a single signal.
The manufacturer of the branded ophthalmic biologic aflibercept alleges that several biosimilar developers' proposed follow-on products infringe a common set of thirteen patents covering the reference biologic.
Appellate review affirmed preliminary injunctions against some defendants while denying one against another, whose product has since launched, reflecting product-specific and manufacturing-specific differences among the biosimilar formulations rather than a single uniform infringement finding.
No. Even within one consolidated proceeding, claim-by-claim and defendant-by-defendant analysis has driven materially different results, and the docket continues to resolve defendant by defendant rather than through one global determination.
That a shared patent-infringement theory asserted against multiple biosimilar developers can still produce genuinely divergent outcomes depending on each product's specific formulation and manufacturing process, a defendant-level distinction Criterica Intelligence tracks across biosimilar patent MDLs.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.